According to IMARC Group’s latest report, titled “Gastroparesis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026; the global gastroparesis drugs market reached a value of US$ XX Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.’
Request for a PDF sample of this report: https://www.imarcgroup.com/gastroparesis-drugs-market/requestsample
The elevating levels of urbanization, the sedentary lifestyles of consumers, and the growing number of individuals who drink or smoke are leading to the rising prevalence of diabetes across the globe. This, along with the expanding geriatric population, who are relatively more susceptible to developing stomach paralysis, is primarily driving the gastroparesis drugs market. Moreover, these drugs help enhance gastrointestinal motility by improving the frequency of contraction. Owing to this, they are being increasingly utilized for treating idiopathic gastroparesis, which is further catalyzing the market growth. Additionally, the increasing number of individuals suffering from gastroparesis after the vague nerve and its branches are damaged during surgical operations is also propelling the product demand. Apart from this, the improving healthcare infrastructures and the inflating demand for user-friendly drugs are augmenting the global market. Furthermore, various leading manufacturers are developing numerous advanced and effective drugs that can be administered via the nasal cavity of individuals. This, in turn, is projected to stimulate the gastroparesis drugs market over the forecasted period.
- Abbott Laboratories
- Abbvie Inc
- AstraZeneca Plc
- Bausch Health Companies Inc
- Becton Dickinson and Company
- Boston Scientific Corporation
- Evoke Pharma
- Medtronic plc
- Neurogastrx Inc.
- Sanofi S.A
- Takeda Pharmaceutical Company Limited
- Theravance Biopharma
Key Market Segmentation:
Breakup by Disease Type:
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
- Post-surgical Gastroparesis
Breakup by Drug Class:
- Prokinetic Agents
- Antiemetic Agents
- Botulinum Toxin Injections
Breakup by Distribution Channel:
- Hospitals and Clinics
- Online Stores
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Others)
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://bit.ly/3AAH0NZ
We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021-2026)
- Market Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800